Marshall Wace North America’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Marshall Wace North America’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-14,856	Closed	-$1.84M	–	1859
2020 Q4	$1.84M	Buy	+14,856	New	+$1.95M	0.01%	779
2020 Q2	–	Sell	-13,107	Closed	-$1.89M	–	1567
2020 Q1	$1.89M	Buy	+13,107	New	+$2.53M	0.01%	493
2018 Q2	–	Sell	-19,473	Closed	-$399K	–	1785
2018 Q1	$399K	Buy	+19,473	New	+$501K	﹤0.01%	1203

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Marshall Wace North America's RETA Position: Q1 2021 in Review

Marshall Wace North America sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2021, closing a stake of 14,856 shares — an estimated $1.84M sold.

Marshall Wace North America first reported a position in RETA in Q1 2018 and held it in 3 quarters. The position peaked at $1.89M in Q1 2020. 201 funds tracked by Wall St. Rank hold RETA as of Q1 2021.

Marshall Wace North America reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2021 after selling out during the quarter.
Marshall Wace North America sold 14,856 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2021, an estimated $1.84M.
Marshall Wace North America first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2018 and held it in 3 quarters.
Marshall Wace North America's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.89M in Q1 2020.
201 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.